Framatome and Nuclearelectrica take the next step in producing cancer-fighting Lutetium-177 in Romania

Must Read

Cushman & Wakefield Echinox: Increased supply of industrial & logistics spaces in 2024, as the stock reached almost 7.6 million sq. m

Bucharest, February 2025 - RBJ - Developers completed new projects with a leasable area of 572,000 sq. m across...

Randstad Romania HR Trends 2025 Study: Higher Salaries by 6-10% for Romanian Employees in 2025

Bucharest, February 7, 2025 - RBJ - Over 80% of employers in Romania plan to raise salaries in 2025,...

Genuin, a growing start-up, 3 years of sustainability and innovation in the home & deco industry in Romania

Bucharest, February 6, 2025 - RBJ - Genuin, the Romanian family-owned brand specializing in organic home & deco products...

Bucharest, October 15, 2024RBJ (Source: Framatome) – Framatome, global company and leader in the field of nuclear energy, and the Romanian company SN Nuclearelectrica SA (BVB:SNN) have announced the successful outcome of the feasibility study which assessed the possibility of producing medical isotope Lutetium-177 (Lu-177) at the Cernavoda nuclear power plant in Romania. Lutetium-177 is used for a variety of lifesaving cancer treatments.

The two companies have now launched the implementation of the project, covering detailed engineering, procurement, installation and the commissioning of the irradiation system at Unit 2 of the Cernavoda nuclear power plant. The launch of a full-scale commercial irradiation service for medical isotopes is targeted for 2028.

“We are proud to have reached this milestone with Nuclearelectrica and to take this important project on to the next phase. Bringing additional capacities from nuclear power reactors helps build a large scale, reliable and diversified supply of critical radioisotopes to fight cancer “, said François Gauché, VP Framatome Healthcare. “The demand for massively accessible cutting-edge cancer treatments globally is growing rapidly. The nuclear industry stands ready to play its part in strengthening the supply chain for lifesaving radioisotopes in Europe and across the world.”

The feasibility study was initiated in November 2023, based on Framatome’s isotope production technology. It assessed whether the infrastructure at Cernavoda could be used to convert targets into medical isotopes in addition to the current generation of reliable, low-carbon electricity. The study demonstrated that by adapting Framatome’s technology to Unit 2 of the Cernavoda nuclear power plant, the reactor would be able to irradiate Ytterbium-176 at the market technical standard required to produce Lutetium-based radiopharmaceuticals.

“Nuclearelectrica is committed to advancing not only energy production but also public health. The production of Lutetium-177 marks a significant milestone for Romania and the global nuclear industry. Our role in supporting cutting-edge oncological treatments through nuclear medicine solidifies the role of nuclear energy in enhancing human well-being,” said Cosmin Ghita, CEO of Nuclearelectrica. “This project highlights the multifaceted contributions that nuclear power can make – clean energy generation and life-saving medical isotopes.”

This project also aims at securing an appropriate supply of Lu-177 to meet Romania’s domestic needs for radiopharmaceutical production and supply.

Lu-177 is a beta-emitting radioisotope used in targeted radionuclide therapy for the treatment of prostate cancer and in multiple promising radiopharmaceutical developments for other cancer indications. The isotope destroys cancer cells while leaving healthy cells unaffected. Framatome’s proprietary isotope production technology enabled the first large-scale commercial production of Lu-177 in a power reactor in June 2022.

- Advertisement -
Latest News

Cushman & Wakefield Echinox: Increased supply of industrial & logistics spaces in 2024, as the stock reached almost 7.6 million sq. m

Bucharest, February 2025 - RBJ - Developers completed new projects with a leasable area of 572,000 sq. m across...

Randstad Romania HR Trends 2025 Study: Higher Salaries by 6-10% for Romanian Employees in 2025

Bucharest, February 7, 2025 - RBJ - Over 80% of employers in Romania plan to raise salaries in 2025, with most increases expected to...

Genuin, a growing start-up, 3 years of sustainability and innovation in the home & deco industry in Romania

Bucharest, February 6, 2025 - RBJ - Genuin, the Romanian family-owned brand specializing in organic home & deco products made from 100% European linen,...

The Government approved the draft budget for 2025: economic growth of 2.5%, inflation of 4.4% and investments of 7.8% of GDP

Bucharest, February 1, 2025 - RBJ - The Government adopted on Saturday, February 1, the draft budget for 2025 and sent it to Parliament...

OVES Enterprise accelerates innovation investments, allocating €3 million for R&D in 2025

Cluj-Napoca/Romania, January 28th, 2025 - RBJ - OVES Enterprise, a Romanian software development company specializing in complex software solutions and AI innovations for the...
- Advertisement -

More Articles Like This

- Advertisement -